Ten New Chapter 99 Codes Go Live July 31, and Eight of Them Collect Nothing

An entry summary that omits a required Chapter 99 heading does not clear. For most of the importers touched by Proclamation 11020 (91 FR 18183), that is the whole exposure, and it has almost nothing to do with the number in the headlines.

As of 12:01 a.m. eastern time on July 31, 2026, every entry of a good classified in one of the roughly 131 tariff provisions enumerated in U.S. note 40 to subchapter III of chapter 99 must carry one of ten new headings, 9903.04.60 through 9903.04.69. Eight of those ten collect no additional duty whatsoever. The declaration obligation is universal from July 31. The 100% duty is not. If your team read the coverage in April, concluded this was a pharmaceutical story, and moved on, the risk you are carrying into next week is a rejected entry summary on a tariff code that collects nothing.

What actually changed, heading by heading

The proclamation inserted a new U.S. note 40 and ten new headings into chapter 99. The headings are mutually exclusive: an article falls under no more than one of them. Together they sort every entry of a covered tariff line into one of four families.

The default and its country tiers. Heading 9903.04.60 is the 100% rate, and it applies to patented pharmaceutical articles unless another heading fits. Note the arithmetic: for 9903.04.60 and 9903.04.62, the sum of the column 1 rate and the Section 232 rate equals the stated rate, and where column 1 already exceeds it, no additional duty is due. Products of Japan, an EU member country, South Korea, Switzerland or Liechtenstein fall under 9903.04.62 at a combined 15%. Products of the United Kingdom fall under 9903.04.63, which is additive: column 1 plus 10 percentage points.

The agreement tiers. Heading 9903.04.64 covers articles of companies with an onshoring plan approved by Commerce, at column 1 plus 20 points, rising to 100% on April 2, 2030. Heading 9903.04.65 covers companies with both an approved onshoring plan and a Most-Favored-Nation pricing agreement with Health and Human Services, at column 1 plus zero, and it expires January 20, 2029. CBP has stated that, per notification from Commerce, no company is currently eligible to file under 9903.04.64.

The zero-rate carve-outs. Heading 9903.04.66 covers specialty categories including orphan-designated drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates and CBRN medical countermeasures. Heading 9903.04.67 covers generic pharmaceutical articles, which the proclamation leaves outside Section 232 for now. Heading 9903.04.68 covers pharmaceutical products with an active pharmaceutical ingredient packaged in dosage form that is a product of the United States. All three are zero.

The timing valve and the residual. Heading 9903.04.61 is the one most importers will actually file: zero additional duty for patented pharmaceutical articles of companies not named in Annex III, entered before 12:01 a.m. eastern time on September 29, 2026. And heading 9903.04.69 is the residual, at zero: articles classified in one of the enumerated provisions that are not pharmaceutical articles at all.

That last heading is the one to sit with.

Where this sits in the 2026 Section 232 sequence

This is the fourth major Section 232 build-out of the year, after the metals adjustments, copper and semiconductors. The pattern by now is familiar to any trade compliance team: a proclamation, a Chapter 99 subchapter, a CBP filing message, and a scramble to map SKUs against an annex.

One thing here is structurally new, and it breaks an assumption most compliance programs are built on. In the metals programs, an importer could determine its own rate from public documents: classification, origin, and in some cases a melt-and-pour or smelt-and-cast declaration. Under Proclamation 11020, the applicable rate for a patented pharmaceutical article can depend on a company-specific agreement that Commerce communicates privately to CBP. Annex II records thirteen agreements concluded before the proclamation. Annex III names seventeen companies whose treatment begins July 31 rather than September 29. Whether a given entry files at 100% or at zero can turn on a notification that is not published in the tariff schedule, in the Federal Register notice, or in CBP's guidance.

For an importer of record operating under reasonable care, that is a genuinely different problem. You cannot self-determine the rate from the instrument. You have to source it from the party that holds the agreement, and you have to be able to show how you sourced it.

Why this lands on the Trade Director's desk, not the regulatory affairs team's

Scope here is defined by tariff line, not by product use. Note 40 applies to articles classifiable in the provisions enumerated in subdivision (c), a closed list of roughly 131 ten-digit codes in chapters 29 and 30. Heading 9903.04.69 exists precisely because some of the goods entering under those codes are not pharmaceutical articles in any sense.

Take a common corridor profile. An industrial manufacturer imports an organic chemical intermediate for a coatings or adhesives formulation. The product has no therapeutic use, no FDA listing, no patent relevance. But its ten-digit classification happens to sit in a 2933 or 2934 line that appears in subdivision (c). Nothing about the duty changes for that importer: 9903.04.69 collects zero. Everything about the filing changes. From July 31, that entry needs a Chapter 99 heading it has never carried, declared by a filer who had no reason to read a pharmaceutical proclamation.

Nobody sends that importer a notice. The tariff line is the trigger, and the tariff line does not know what the product is for.

There is a second reason the compliance calendar matters more than the duty calendar. The list of covered provisions is not the list published in April. The 484(f) Committee changes effective July 1, 2026 revised ten-digit statistical reporting numbers, and CBP's guidance points to subdivision (c) as updated by those changes. USITC published HTS Revision 13 on July 28. A SKU map built against the April annex is a stale map.

Three more provisions deserve a place on the same checklist. Under note 40(b), the duties in these headings are collected in addition to any special rate available under a free trade agreement or preference program, so a USMCA claim does not shield a covered article. Chapter 98 entries remain eligible under their own terms, but no Chapter 99 provision offering a lower rate or duty-free treatment may be claimed against these headings. And covered goods admitted to a foreign trade zone on or after the effective date must be admitted as privileged foreign status under 19 CFR 146.41, not privileged as an afterthought at withdrawal.

One favorable note, unusual for a Section 232 action: drawback is available on these duties.

The four checks to run before your next entry

1. Rebuild the covered-lines map against the current HTS revision. Pull the subdivision (c) list as reflected in CBP's guidance and the July 1 statistical changes, then run it against your active classification master, not your catalog. You are looking for any ten-digit code you file that appears on that list, including codes on products with no pharmaceutical connection.
2. Assign a heading to every match, and document the reasoning. For each covered line, determine which of the ten headings applies and write down why. For non-pharmaceutical goods, that is 9903.04.69 and the file should say so plainly. For patented articles, the answer depends on origin, on specialty category, and in some cases on a company agreement you do not control.
3. Get the company-specific status in writing. If any covered entry involves a product of an Annex III company, or a claim under headings 9903.04.64 through 9903.04.66, obtain written confirmation of the applicable treatment from the party that holds the agreement. Note 40(h) puts the information burden on the importer entering under those headings. A verbal assurance from a supplier is not a reasonable care file.
4. Confirm your filer is provisioned before the first entry, not after the first reject. Codes that are new in ACE fail quietly and then loudly. Confirm with your broker that the headings are live in their system and that the mapping to your covered lines is loaded. For zone operations, confirm the admission status question is settled for cargo already in the zone.

Across more than 190,000 customs operations a year at 39+ ports, the failures that follow a change like this cluster in one place: not in the operations that owed the duty and knew it, but in the operations that owed nothing and never learned they were in scope. The duty gets modeled because it shows up in a budget. The declaration gets missed because it does not.

The code that collects nothing is the one that stops the entry

Two dates now sit in front of every importer of a covered line. September 29 is when the money starts for companies outside Annex III. July 31 is when the filing starts for everyone, at whatever rate applies, including zero.

The second date is the one with less margin and less warning. A duty you did not model is a variance you explain next quarter. A Chapter 99 heading you did not file is cargo that does not move.

Talk to a Joffroy expert about a covered-lines review against the current HTS revision for your chapter 29 and 30 classifications, on both sides of the border, before your next entry.

TRADE. UNDER CONTROL.